Welcome to "11 O'Clock Stock." Here at Fool.com, we'll be finding a new great stock at 11 a.m. ET every weekday for 50 days. Better yet, we're so confident in the picks, we're investing $50,000 of the Fool's own money in them! To hear more about the series, click here to see a video from Motley Fool co-founder Tom Gardner. Can't make it at 11 a.m. ET? Come back to Fool.com, and we'll have the article in our Top Stories section 24 hours a day.
There are blue chips, and then there are Blue Chips. And then there's Johnson & Johnson
In a sense, the investment case for Johnson & Johnson is very simple: Here's a company that's been around forever (technically, since 1886), that pays a 3.5% dividend, and that's spread across arguably the most necessary sector (behind water and sewage): health care.
But during the past year, trouble entered paradise. First, nasties like metal shavings, bacteria, and just plain dirt were found in children's Tylenol and about 40 other drugs manufactured by J&J's apparently not-well-supervised subsidiary, McNeil Pharmaceuticals. Then there was a contact lens recall. And most recently, J&J's DePuy unit announced that it was voluntarily recalling people's hips -- not exactly the type of thing you want to have re-replaced. (Officially, the recall is only advised if your artificial joint is causing trouble.)
But Fool, J&J is a big, big ship. These bad headlines are just that: bad headlines. Unlike, say, with Merck's
In fact, negative headlines could mean a good buying opportunity for this company that has paid dividends since 1944. J&J's diversified revenue comes from three main groups: pharmaceuticals, which competes with big dogs like Pfizer
Speaking of management, J&J is known for its solid corporate governance -- inadequate oversight of its recall-prone subsidiaries notwithstanding -- and I dig that CEO Bill Weldon has been with the company for nearly 40 years.
Truth be told, I'm a little skeptical about Big Pharma for its dependence on chemical-based drug discovery, which has showed declining productivity in recent years. But I like that J&J's pharma division has one of the strongest pipelines in the industry, meaning it should sail through near-term patent expirations on former blockbusters better than many of its peers.
One thing I'm a believer in is valuation for stalwart companies like J&J, and according to my model, J&J is priced for 25% upside. Combined with its growing dividend -- raised 7.5% in the last 12 months alone -- it's an attractive package. But at the end of the day, the story is more obvious: More people in our society are living longer, which means more medicine. In turn, that means more business for Johnson & Johnson -- and more money for shareholders like you and me.
Previous 11 O'Clock Stock recommendations:
- CGG Veritas
- Cal-Maine Foods
- Track the performance of our full list of recommendations.
Come back to Fool.com Monday for another great stock pick. There's plenty more great stock advice, and you can find video of each day's recommendation as well! To see the performance of previous recommendations, click here.
The Motley Fool will wait at least 24 hours after this publication before buying shares of Johnson & Johnson. To see an FAQ on the "11 O'Clock Stock," click here.
James Early owns shares of Johnson & Johnson. Pfizer and Stryker are Motley Fool Inside Value picks. GlaxoSmithKline is a Motley Fool Global Gains recommendation. Johnson & Johnson is a Motley Fool Income Investor recommendation. Motley Fool Options has recommended a diagonal call position on Johnson & Johnson. The Fool owns shares of GlaxoSmithKline and Medtronic. True to its name, The Motley Fool is made up of a motley assortment of writers and analysts, each with a unique perspective; sometimes we agree, sometimes we disagree, but we all believe in the power of learning from each other through our Foolish community. The Motley Fool has a disclosure policy.